ZTSZoetis Inc.

$54B

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$9.3B+8.3% YoY

Gross Profit

$6.4B69.1% margin

Operating Income

$3.4B36.6% margin

Net Income

$2.5B26.9% margin

EPS (Diluted)

$5.47

Cash Flow

Operating Cash Flow

$3.0B

Free Cash Flow

$2.3B

Stock-Based Comp.

$74M

Balance Sheet

Total Assets

$14.2B

Total Liabilities

$9.5B

Stockholders' Equity

$4.8B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9.3B	$8.5B	+8.3%
Gross Profit	$6.4B	$5.8B	+9.6%
Operating Income	$3.4B	$3.1B	+10.5%
Net Income	$2.5B	$2.3B	+6.1%

ZTS FY 2024 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena